DRUG

Bevacizumab

Metastatic colorectal cancer (FDA 2004) and other malignancies

23 hypotheses across 8 therapeutic domains

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

Bevacizumab appears in hypotheses across 8 disease domains: ALS, Alzheimer, Depression, Epilepsy, Inflammatory bowel disease, Multiple sclerosis, Rheumatoid arthritis, Type 2 diabetes. Shared mediators that recur across at least two of those domains: VEGF.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for Bevacizumab

ALS 2

Mediator Outcome Score Tier Lit. status Trial
VEGF susceptibility to neurodegeneration 0.248 Mid novel signal none
VEGF motoneuron cell death 0.248 Mid novel signal none

Alzheimer 4

Mediator Outcome Score Tier Lit. status Trial
VEGF Alzheimer's disease 0.289 High partial evidence none
VEGF amyloid-β burden 0.248 Mid novel signal none
VEGF tau burden 0.248 Mid novel signal none
VEGF Vascular dementia 0.248 Mid novel signal none

Depression 3

Mediator Outcome Score Tier Lit. status Trial
VEGF depressive symptom severity 0.248 Mid novel signal none
VEGF antisuicidal effects of ketamine 0.248 Mid novel signal none
VEGF antidepressant response to ketamine 0.248 Mid novel signal none

Epilepsy 3

Mediator Outcome Score Tier Lit. status Trial
VEGF hippocampal neuron loss 0.248 Mid novel signal none
VEGF BBB permeability 0.248 Mid reproduces known none
VEGF cerebral vascular abnormalities 0.248 Mid novel signal active

Inflammatory bowel disease 1

Mediator Outcome Score Tier Lit. status Trial
VEGF glucocorticoid-free remission 0.248 Mid novel signal none

Multiple sclerosis 1

Mediator Outcome Score Tier Lit. status Trial
VEGF Multiple Sclerosis 0.248 Mid reproduces known none

Rheumatoid arthritis 7

Mediator Outcome Score Tier Lit. status Trial
VEGF SDAI 0.248 Mid novel signal none
VEGF active infection 0.248 Mid partial evidence none
VEGF psoriatic arthritis 0.248 Mid reproduces known none
VEGF RA disease activity 0.248 Mid novel signal none
VEGF DAS28 0.248 Mid novel signal none
VEGF rheumatoid arthritis 0.248 Mid reproduces known none
VEGF swollen joint count 0.248 Mid novel signal none

Type 2 diabetes 2

Mediator Outcome Score Tier Lit. status Trial
VEGF diabetic retinopathy 0.248 Mid reproduces known active
VEGF enlarged foveal avascular zone 0.248 Mid partial evidence none

Clinical trials

200 registered trials for Bevacizumab

Source: ClinicalTrials.gov

← All drugs